Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 409.99M P/E - EPS this Y 64.60% Ern Qtrly Grth -
Income -29.34M Forward P/E 10.85 EPS next Y 67.10% 50D Avg Chg -4.00%
Sales 308.13M PEG 0.06 EPS past 5Y - 200D Avg Chg -36.00%
Dividend N/A Price/Book N/A EPS next 5Y -25.10% 52W High Chg -69.00%
Recommedations 2.10 Quick Ratio 1.02 Shares Outstanding 115.21M 52W Low Chg 21.00%
Insider Own 1.39% ROA -16.05% Shares Float 103.30M Beta 0.67
Inst Own 74.70% ROE - Shares Shorted/Prior 25.09M/24.01M Price 4.34
Gross Margin 41.51% Profit Margin -9.52% Avg. Volume 3,723,385 Target Price 9.50
Oper. Margin -31.56% Earnings Date Nov 4 Volume 4,840,432 Change -3.34%
About Coherus BioSciences, Inc.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Coherus BioSciences, Inc. News
11/07/24 Q3 2024 Coherus BioSciences Inc Earnings Call
11/07/24 Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
11/06/24 Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates
11/06/24 Coherus BioSciences: Q3 Earnings Snapshot
11/06/24 Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
10/30/24 Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
10/09/24 Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
09/28/24 Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now
09/25/24 Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges
09/20/24 Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses
08/10/24 Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations
08/08/24 Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
08/08/24 Coherus BioSciences: Q2 Earnings Snapshot
08/08/24 Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
08/01/24 Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
06/28/24 PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
06/27/24 Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
06/05/24 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
04:51 PM Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
05:17 AM We Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation
CHRS Chatroom

User Image AGI2018 Posted - 8 minutes ago

$CHRS $CHRS An1ka therap generated $38.8M in revenue in Q3 & its market cap is $255m and ChRS generated $70m and its market cap is $126m chrs should be trading way higher

User Image Biotech2424 Posted - 10 hours ago

$CHRS I think we should be getting some good news via press release next week.

User Image omega42 Posted - 10 hours ago

$CHRS yeah, its always very comforting to hear about all these M&As and BOs while your account is tanking

User Image HighClubSpeed Posted - 10 hours ago

$CHRS this board is good people, I don’t see this vibe often on ST, glad you’re all here ☮️ good things coming

User Image John1878 Posted - 10 hours ago

$CHRS posted this as clearly a lot of new investors on the board so saving you time/research. However, I’m quite high level so if you want technical expertise from the longest standing investors then @neofeudal and @Tonee1234 should be your go to guys. Enjoy the weekend all!

User Image DanishViking92 Posted - 10 hours ago

$CHRS This green chart looks quite damn good for next week.. havent seen a biotech stock perform this good in a very loong time. Have a nice weekend folks! See you next week ;)

User Image Microcap777 Posted - 10 hours ago

$CHRS If this is not a cup and handle, what the fuck is?

User Image Biotech2424 Posted - 11 hours ago

$CHRS Coherus is in the early infancy of same move Sangamo had over past few months with the blow out quarter they had. $SGMO

User Image 0fabiocoppola Posted - 11 hours ago

$CHRS SGMO$ in 3 months 1000%

User Image 0fabiocoppola Posted - 11 hours ago

$CHRS who doesn't buy now will be ruined

User Image Biotech2424 Posted - 11 hours ago

Shorts just trying to buy as much back at $1.10 Before game is over for him $CHRS

User Image Sgt_Farva Posted - 11 hours ago

$CHRS

User Image Biotech2424 Posted - 11 hours ago

$CHRS Game over bulls are taking over

User Image Damnthisappilosthistory Posted - 11 hours ago

$CHRS you guys think this is a good entry price? Or wait for a pullback?

User Image MarketPro Posted - 12 hours ago

$CHRS Are we getting a good close? Cause it looks like we are gonna get a good close....

User Image Biotech2424 Posted - 12 hours ago

$CHRS Moving higher!

User Image neofeudal Posted - 13 hours ago

Accumulation zone. $CHRS

User Image John1878 Posted - 13 hours ago

$CHRS Reasons to invest - 1) Downtrend channel break 2) Above 50 day ma 3) Tip ranks shows online searches up 130% 4) Fair value circa $7 5) Cf+ within next 3-6 months 6) Udenyca gaining 20/30% market share q on q 6) Tori huge long term potential with expected 50% increase in sales q on q 7) Shorts covering from reduced float 8) Circa 80-85% instit ownership 8) Reduced cmo cost 9) Circa $100 mln bank 10) Recent reduced headcount cost 11) Royalty payments from Tori canada outsourcing 12) Analysts re confirming buy ratings Potential downsides - 1) Bonds due April 26 2) If cf+ not achieved risk cash burn 3) Trump blocking any Chinese linked Pd1 Always good to run an upside risk v downside risk but do your own dd. Nothing is risk free in life but some investments offer significantly greater opportunity than others.

User Image NotOfTheBody Posted - 13 hours ago

$CHRS Decent volume along with some good dip buying in the $1.08 range.

User Image Tonee1234 Posted - 13 hours ago

$CHRS this was all sophisticated financial engineering everyone knew that some decided to try to ride it to the equations theoretical 0 others will dca down and up as investors me...I just like the science and analytics

User Image Sgt_Farva Posted - 13 hours ago

$CHRS got some stink bids in under a buck just in case

User Image neofeudal Posted - 13 hours ago

$CHRS

User Image neofeudal Posted - 13 hours ago

$CHRS "Forward buying in light of the supply issue"? Think about that. You are saying that while product was not available and doctors had to substitute with medicine that has been consumed by their patients, they will now BUY AHEAD as product comes back online? Nonsense talk. Coherus will have experienced added expense weighing on earnings that will be relieved as product ships, though. So, you have it 100% backwards, it appears.

User Image Tonee1234 Posted - 14 hours ago

$CHRS market buy works for me; no need to quibble over a few FULL PENNY's these days

User Image Epic_dude0 Posted - 14 hours ago

$CHRS ascending triangle… can we flip green on the second half of today’s market?

User Image Wisenheimer Posted - 14 hours ago

$CHRS you cant compare mkt caps thats kids math - you have to look at enterprise value for $40mm ASRT vs $300mm CHRS - that more accurate and dont assume most recent rev is a trend - lots of forward buying in light of the supply issue.

User Image Damnthisappilosthistory Posted - 14 hours ago

$CHRS what big news is expected in short term?

User Image DanishViking92 Posted - 15 hours ago

$CHRS Soon we will all wake up and see this at +300% when short squeeze on big news occurs

User Image duckieman1026 Posted - 15 hours ago

$CHRS Newbie here. Did some research and took out some $3 c 1/16/26 leaps. Gonna hold and enjoy.

User Image Sgt_Farva Posted - 15 hours ago

$CHRS Just bought 75,000 here. Will average in another 75,000 at $1.00 levels. Revenue will hit 100 million a quarter here by second half 2025. Getting in on bottom

Analyst Ratings
HC Wainwright & Co. Buy Sep 16, 24
UBS Neutral Aug 16, 24
HC Wainwright & Co. Buy Aug 5, 24
Baird Outperform Jul 1, 24
HC Wainwright & Co. Buy May 24, 24
Truist Securities Buy May 13, 24
HC Wainwright & Co. Buy May 10, 24
HC Wainwright & Co. Buy Mar 20, 24
HC Wainwright & Co. Buy Mar 14, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wahlstrom Mats Director Director Feb 01 Option 1.67 59,988 100,180 99,988 02/05/24
Lanfear Dennis M President & CEO President & CEO Nov 22 Sell 2.02 223,100 450,662 731,693 11/24/23
Lanfear Dennis M President & CEO President & CEO Nov 22 Option 1.42 299,940 425,915 954,793 11/24/23
Vexler Vladimir Chief Scientific Off.. Chief Scientific Officer Mar 11 Option 7.14 102,480 731,707 167,626 03/11/21
Vexler Vladimir Chief Scientific Off.. Chief Scientific Officer Mar 11 Sell 16.25 114,240 1,856,400 53,386 03/11/21
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Mar 09 Option 9.3 20,312 188,902 80,051 03/09/21
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Mar 09 Sell 15.46 26,649 411,994 53,402 03/09/21
Viret Jean-Frederic Chief Financial Offi.. Chief Financial Officer Feb 03 Option 10.05 7,402 74,390 68,697 02/03/21
Viret Jean-Frederic Chief Financial Offi.. Chief Financial Officer Feb 03 Sell 21.55 7,402 159,513 61,295 02/03/21
Viret Jean-Frederic Chief Financial Offi.. Chief Financial Officer Jan 27 Option 10.05 40,000 402,000 107,439 01/27/21
Viret Jean-Frederic Chief Financial Offi.. Chief Financial Officer Jan 27 Sell 19.55 46,144 902,115 61,295 01/27/21
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Dec 09 Option 12.54 8,791 110,239 41,360 12/09/20
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Dec 09 Sell 18.42 8,791 161,930 32,569 12/09/20
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Nov 19 Option 7.6 6,783 51,551 36,852 11/19/20
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Nov 19 Sell 17.71 22,770 403,257 32,569 11/19/20